Escolar Documentos
Profissional Documentos
Cultura Documentos
Teriparatida (PTH[1-34]rh):
Uma nova perspectiva no tratamento da osteoporose
Teriparatide (PTH[1-34]rh): A new perspective in the treatment of osteoporosis
JULIANA HELENA ABREU DE OLIVEIRA(1), OSWALDO LUÍS BRACCO(1), MARCIA KAYATH(1), ROBERTO GUARNIERO(2)
RESUMO SUMMARY
No momento, as medicações aprovadas para tratamento Medications currently approved for treatment of osteoporo-
da osteoporose agem reduzindo a taxa de perda óssea e dimi- sis act by slowing the rate of bone loss and decreasing bone
nuindo a reabsorção óssea. A teriparatida é um fragmento re- resorption. Teriparatide is a synthetic recombinant 34-amino-acid
combinante sintético de 34 aminoácidos do hormônio paratire- fragment of human parathyroid hormone. Teriparatide binds to
óide humano. A teriparatida se liga ao receptor de PTH da pro- the G protein PTH receptor and stimulates the action of osteo-
teína G e estimula a formação e a ação dos osteoblastos, que blasts, which are the cells responsible for bone formation. Thus
são as células responsáveis pela formação dos ossos. Assim, the main difference between teriparatide and antiresorptive the-
a principal diferença entre o tratamento da osteoporose com rapy for osteoporosis is that the former promotes the growth of
teriparatida e o tratamento anti-reabsorção é que a teriparatida new bone. In preclinical studies intermittent PTH has been asso-
promove o crescimento de osso novo. Em estudos pré-clíni- ciated with a significant increase in cancellous bone mass at
cos, o uso intermitente de PTH foi associado com um aumento several sites. Intermitent exposure to PTH for 4-6 weeks in ovari-
significativo da massa óssea gradeada em diversos locais. A ectomized animal models leads to increased cancelous bone
exposição intermitente ao PTH durante 4 a 6 semanas em mo- thickness. Clinical trials have shown that teriparatide significantly
delos de animais ovariectomizados leva a um aumento da es- increases bone density and reduces the incidence of vertebral
pessura do osso gradeado. Há estudos clínicos que mostram and non-vertebral osteoporotic fractures in women with postme-
que a teriparatida aumenta significativamente a densidade ós- nopausal osteoporosis at high risk of fractures and increases bone
sea e diminui a incidência de fraturas osteoporóticas vertebrais density in men with either hypogonadal or idiopathic osteoporo-
e não-vertebrais nas mulheres com osteoporose pós-menopáu- sis. It is administrated daily via subcutaneous injection, and has
sica e têm risco alto de fratura, e aumenta a densidade óssea been associated with minimal side effects and no reported drug
nos homens com osteoporose, tanto hipogonádica como idio- interactions. Therefore, teriparatide emerges as a completely new
pática. A teriparatida é dada por injeção subcutânea diária e foi approach in the treatment of osteoporosis, directly stimulating
associada com um mínimo de efeitos colaterais, além de não new bone formation.
apresentar interações medicamentosas. Sendo assim, a teri-
paratida surge como uma abordagem completamente nova no
tratamento da osteoporose, estimulando diretamente a forma- Key words: Parathyroid hormones; Teriparatide; Osteoporosis.
ção do osso.
Trabalho realizado na Divisão Médica/Pesquisa Clínica Eli Lilly do Brasil This work was performed at the Eli Lilly do Brasil Clinical Research, Medical Division
1 - Endocrinologistas, Pesquisadores Clínicos 1 - Doctors, Clinical Research
2- Professor Associado do IOT-FMUSP 2 - Associate Professor of IOT-FMUSP
REFERÊNCIAS BIBLIOGRÁFICAS
1. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermit- 15. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teripa-
tently administered human parathyroid hormone (1-34) treatment increases intracor- ratide is largely independent of age, initial bone mineral density, and prevalent verte-
tical bone turnover and porosity without reducing bone strength in the humerus of ral fractures in postmenopausal women with osteoporosis. J Bone Miner Res, 18:18-
ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165, 2001. 23, 2003.
2. Carter PH, Shimizu M, Luck MD, Gardella TJ. The hydrophobic residues 16. Nakajima A, et al.: Mechanisms for enhancement of fracture healing in rats
phenylalanine 184 and leucine 187 in the type-1 parathyroid hormone (PTH) recep- treated with intermitent low-dose human parathyroid hormone (1-34). J Bone Miner
tor functionally interact with the amino-terminal portion of PTH-(1-34). J Biol Chem Res 17:2038-2047, 2002.
274:31955-31960, 1999. 17. Neer R, Arnaud CD, Zanchetta JR et al. Effect of parathytoid hormone (1-34)
3. Cheng PT, Chan C, Muller K. Cyclical treatment of osteopenic ovariectomized on fractures and bone mineral density in postmenopausal women with osteoporosis.
adult rats with PTH (1-34) and pamidronate. J Bone Miner Res 10:119-126, 1995. N Engl J Med 344:1434-1441, 2001.
4. Cosman F, Nieves J, Woelfert L, Gordon S, Shen V, Lindsay R. Parathyroid 18. Orwoll ES, et al. The effect of Teriparatide [Human Parathyroid Hormone (1-
responsivity in postmenopausal women with osteoporosis during treatment with pa- 34) therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17,
rathyroid hormone. J Clin Endocrinol Metab 83:788-790, 1998. 2003.
5. Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with 19. Oxlund H, Dalstra M, Ejersted C, Andreassen TT. Parathyroid hormone indu-
parathyroid hormone on bone microarchitecture and turnover in patients with osteo- ces formation of new cancellous bone with substantial mechanical strength at a site
porosis: a paired biopsy study. J Bone Miner Res 16:1846-1853, 2001. where it had disappeared in old rats. Eur J Endocrinol 146:431-438, 2002.
6. Hock JM, Gera I, Fonseca J, Raisz LG. Human parathyroid hormone (1-34) 20. Parisien M, Cosman F, Mellish RW et al. Bone structure in postmenopausal
increases bone mass in ovariectomized and orchidectomized rats. Endocrinology hyperparathyroid, osteoporotic and normal women. J Bone Miner Res 10:1393-1399,
122:2899-2904, 1988. 1995.
7. Hock JM, Gera I. Effects of continous and intermitent administration and inhi- 21. Parisien M, Mellish RW, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP,
bition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Dempster DW. Maintenance of cancellous bone connectivity in primary hyperpara-
Miner Res 7:65-72, 1992. thyroidism: Trabecular strut analysis. J Bone Miner Res 7:913-919, 1992.
8. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC et al. 22. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP,
Increased bone formation by prevention of osteoblast apoptosis with parathyroid Dempster DW. The histomorphometry of bone in primary hyperparathyroidism: pre-
hormone. J Clin Invest 104:439-446, 1999. servation of cancellous bone structure. J Clin Endocrinol Metab 70: 930-938, 1990.
9. Khosla S, Melton LJ, Wermers RA, Crowson CS, O’Fallon W, Riggs B. Primary 23. Reeve J, Meunier PJ, Parsons JA. Anabolic effect of human parathyroid hor-
hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner mone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br
Res 14:1700-1707, 1999. Med J 280 (6228): 1340-4, 1980.
10. Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged 24. Reid IR. Pharmacological management of osteoporosis in postmenopausal
estrogen-depleted rats after long-term intermittent treatment with parathyroid hor- women: a comparative review. Drugs Aging 15:349-63, 1999.
mone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28:237-250, 2001. 25. Rodan GA, Martin TJ. Therapeutic approches to bone diseases. Science
11. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP et 289:1508-1514, 2000.
al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on 26. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis: J Clin Endocrinol
bone density and bone markers. J Clin Endocrinol Metab 85:3069-3076, 2000. Metab 86:957-964, 2001.
12. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous admi- 27. Rubin MR, Bilezikian JP. The potential of parathyroid hormone as a therapy
nistration of the amino-terminal fragment of human parathyroid hormone-(1-34): ki- for osteoporosis. Int J Fertil 47:103-115, 2002.
netics and biochemical response in estrogenized osteoporotic patients. J Clin Endo-
crinol Metab 77:1535-1539, 1993. 28. Tashjian AH, Chabner BA. Commentary on clinical safety of recombinant
human parathyroid hormone 1-34 in the treatment of osteoporosis in men and post-
13. Lindsay R, Scheele WH, Clancy AD, Hossain A, Mitlak BH. Reduction in menopausal women. J Bone Miner Res 17:1151-1161, 2002.
nonvertebral fragility fractures and increase in spinal bone density is maintained 31
months after discontinuation of recombinant human parathyroid hormone (1-34) in 29. Vahle JL, Sato M, Long GG et al. Skeletal changes in rats given daily subcu-
postmenopausal women with osteoporosis. In: 84th ANNUAL MEETING THE ENDO- taneous injection of recombinant human parathyroid hormone (1-34) for 2 years and
CRINE SOCIETY, San Francisco, 19-22 June, 2002. (Abstract #OR35-6) relevance to human safety. Toxicol Pathol 30:312-321, 2002.
14. Lindsay R, Scheele WH, Clancy AD, Mitlak B. Incident vertebral fractures 30. Watson PH, Lazowski, Fraher LJ, Steer BM, Hodsman AB. PTH restores bone
during an 18 month observation period following discontinuation of ly333334 [re- mass and enhances osteoblast IGF-I gene expression in ovariectomized rats. Bone
combinant human parathyroid hormone (1-34), rhPTH(1-34)] use in postmenopausal 1:61-69, 1995.
women with osteoporosis. J Bone Min Res 16(Suppl 1):S163, 2001.